These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 15280474

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, Adkison KK, Shachoy-Clark A, Piscitelli SC.
    J Clin Pharmacol; 2008 Oct; 48(10):1179-88. PubMed ID: 18676693
    [Abstract] [Full Text] [Related]

  • 23. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S.
    AIDS; 2006 Oct 24; 20(16):2065-73. PubMed ID: 17053352
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
    Owais M, Arya SK.
    J Hum Virol; 1999 Oct 24; 2(5):270-82. PubMed ID: 10551733
    [Abstract] [Full Text] [Related]

  • 26. Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis.
    Mayanja-Kizza H, Wajja A, Wu M, Peters P, Nalugwa G, Mubiru F, Aung H, Vanham G, Hirsch C, Whalen C, Ellner J, Toossi Z.
    J Infect Dis; 2001 Jun 15; 183(12):1801-4. PubMed ID: 11372034
    [Abstract] [Full Text] [Related]

  • 27. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
    Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM.
    Antimicrob Agents Chemother; 2005 Dec 15; 49(12):4911-9. PubMed ID: 16304152
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.
    Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M, Proudfoot AE.
    J Leukoc Biol; 2001 Jun 15; 69(6):977-85. PubMed ID: 11404385
    [Abstract] [Full Text] [Related]

  • 30. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M.
    J Med Chem; 2006 Mar 23; 49(6):2037-48. PubMed ID: 16539392
    [Abstract] [Full Text] [Related]

  • 31. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K, Schols D.
    Cytokine Growth Factor Rev; 2005 Dec 23; 16(6):659-77. PubMed ID: 16005254
    [Abstract] [Full Text] [Related]

  • 32. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.
    Antiviral Res; 2009 Jul 23; 83(1):86-9. PubMed ID: 19501260
    [Abstract] [Full Text] [Related]

  • 33. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
    Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen H, Humblias J, Samson M, Parmentier M, Moore JP, Mackay CR.
    J Exp Med; 1997 Oct 20; 186(8):1373-81. PubMed ID: 9334377
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
    Willey S, Peters PJ, Sullivan WM, Dorr P, Perros M, Clapham PR.
    Antiviral Res; 2005 Nov 20; 68(2):96-108. PubMed ID: 16157392
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M.
    Antimicrob Agents Chemother; 2005 Nov 20; 49(11):4721-32. PubMed ID: 16251317
    [Abstract] [Full Text] [Related]

  • 38. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE, Quiñones-Mateu ME, Arts EJ.
    J Virol; 2000 May 20; 74(10):4868-76. PubMed ID: 10775626
    [Abstract] [Full Text] [Related]

  • 39. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
    Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M.
    Proc Natl Acad Sci U S A; 1999 May 11; 96(10):5698-703. PubMed ID: 10318947
    [Abstract] [Full Text] [Related]

  • 40. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
    Hu Q, Napier KB, Trent JO, Wang Z, Taylor S, Griffin GE, Peiper SC, Shattock RJ.
    J Mol Biol; 2005 Jul 22; 350(4):699-712. PubMed ID: 15964018
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.